In addition, increased serum levels of FABP3 have been reported in patients with metabolic syndrome and non-alcoholic fatty liver disease (51, 52), suggesting that FABP3 may serve as a biomarker of insulin resistance and subclinical myocardial damage. Here, FABP3 is linked to metabolic syndrome.